Legal Representation
Attorney
Shauna M. Wertheim
USPTO Deadlines
Next Renewal Deadline
868 days remaining
Section 8 (6-Year) Declaration Due (Based on registration date 2021-11-23)
Due Date
November 23, 2027
Grace Period Ends
May 23, 2028
Additional deadlines exist. Contact your attorney for complete deadline information.
Application History
50 events| Date | Code | Type | Description |
|---|---|---|---|
| Jun 26, 2025 | COAR | I | TEAS CHANGE OF OWNER ADDRESS RECEIVED |
| Jun 26, 2025 | ARAA | I | ATTORNEY/DOM.REP.REVOKED AND/OR APPOINTED |
| Jun 26, 2025 | CHAN | I | APPLICANT/CORRESPONDENCE CHANGES (NON-RESPONSIVE) ENTERED |
| Jun 26, 2025 | REAP | I | TEAS REVOKE/APP/CHANGE ADDR OF ATTY/DOM REP RECEIVED |
| Jun 26, 2025 | TCCA | I | TEAS CHANGE OF CORRESPONDENCE RECEIVED |
| Dec 26, 2023 | CCON | T | COUNTERCLAIM OPP. NO. 999999 |
| Nov 23, 2021 | R.PR | A | REGISTERED-PRINCIPAL REGISTER |
| Oct 21, 2021 | SUNA | E | NOTICE OF ACCEPTANCE OF STATEMENT OF USE E-MAILED |
| Oct 21, 2021 | EPPA | I | TEAS POST PUBLICATION AMENDMENT RECEIVED |
| Oct 20, 2021 | CNPR | P | ALLOWED PRINCIPAL REGISTER - SOU ACCEPTED |
| Oct 18, 2021 | SUPC | I | STATEMENT OF USE PROCESSING COMPLETE |
| Oct 15, 2021 | IUAF | S | USE AMENDMENT FILED |
| Oct 15, 2021 | EISU | I | TEAS STATEMENT OF USE RECEIVED |
| Jun 23, 2021 | ASGN | I | AUTOMATIC UPDATE OF ASSIGNMENT OF OWNERSHIP |
| Jun 17, 2021 | EXRA | E | NOTICE OF APPROVAL OF EXTENSION REQUEST E-MAILED |
| Jun 16, 2021 | EX5G | S | SOU EXTENSION 5 GRANTED |
| Jun 14, 2021 | AITU | A | CASE ASSIGNED TO INTENT TO USE PARALEGAL |
| May 21, 2021 | NREV | E | NOTICE OF REVIVAL - E-MAILED |
| May 20, 2021 | PROA | I | TEAS PETITION TO REVIVE RECEIVED |
| May 20, 2021 | TPEX | I | SOU EXTENSION RECEIVED WITH TEAS PETITION |
| May 20, 2021 | PETG | O | PETITION TO REVIVE-GRANTED |
| May 17, 2021 | MAB6 | E | ABANDONMENT NOTICE E-MAILED - NO USE STATEMENT FILED |
| May 17, 2021 | ABN6 | S | ABANDONMENT - NO USE STATEMENT FILED |
| Apr 16, 2021 | EXT5 | S | SOU EXTENSION 5 FILED |
| Oct 16, 2020 | EXRA | E | NOTICE OF APPROVAL OF EXTENSION REQUEST E-MAILED |
| Oct 14, 2020 | EX4G | S | SOU EXTENSION 4 GRANTED |
| Oct 14, 2020 | EXT4 | S | SOU EXTENSION 4 FILED |
| Oct 14, 2020 | EEXT | I | SOU TEAS EXTENSION RECEIVED |
| Aug 5, 2020 | TCCA | I | TEAS CHANGE OF CORRESPONDENCE RECEIVED |
| Aug 5, 2020 | ARAA | I | ATTORNEY/DOM.REP.REVOKED AND/OR APPOINTED |
| Aug 5, 2020 | REAP | I | TEAS REVOKE/APP/CHANGE ADDR OF ATTY/DOM REP RECEIVED |
| Mar 12, 2020 | EXRA | E | NOTICE OF APPROVAL OF EXTENSION REQUEST E-MAILED |
| Mar 10, 2020 | EX3G | S | SOU EXTENSION 3 GRANTED |
| Mar 10, 2020 | EXT3 | S | SOU EXTENSION 3 FILED |
| Mar 10, 2020 | EEXT | I | SOU TEAS EXTENSION RECEIVED |
| Oct 4, 2019 | EXRA | E | NOTICE OF APPROVAL OF EXTENSION REQUEST E-MAILED |
| Oct 2, 2019 | EX2G | S | SOU EXTENSION 2 GRANTED |
| Oct 2, 2019 | EXT2 | S | SOU EXTENSION 2 FILED |
| Oct 2, 2019 | EEXT | I | SOU TEAS EXTENSION RECEIVED |
| Mar 27, 2019 | EXRA | E | NOTICE OF APPROVAL OF EXTENSION REQUEST E-MAILED |
| Mar 25, 2019 | EX1G | S | SOU EXTENSION 1 GRANTED |
| Mar 25, 2019 | EXT1 | S | SOU EXTENSION 1 FILED |
| Mar 25, 2019 | EEXT | I | SOU TEAS EXTENSION RECEIVED |
| Oct 16, 2018 | NOAM | E | NOA E-MAILED - SOU REQUIRED FROM APPLICANT |
| Aug 21, 2018 | PUBO | A | PUBLISHED FOR OPPOSITION |
| Aug 21, 2018 | NPUB | E | OFFICIAL GAZETTE PUBLICATION CONFIRMATION E-MAILED |
| Aug 1, 2018 | NONP | E | NOTIFICATION OF NOTICE OF PUBLICATION E-MAILED |
| Jul 17, 2018 | CNSA | P | APPROVED FOR PUB - PRINCIPAL REGISTER |
| Jul 11, 2018 | TEME | I | TEAS/EMAIL CORRESPONDENCE ENTERED |
| Jul 11, 2018 | CRFA | I | CORRESPONDENCE RECEIVED IN LAW OFFICE |
Detailed Classifications
Class 005
pharmaceutical preparations for the treatment of cancer; anti-cancer preparations; vaccines; vaccine preparations
First Use Anywhere:
Mar 18, 2019
First Use in Commerce:
Mar 18, 2019
Class 009
next-generation sequencing (NGS) data processor; bioinformatics data processor; downloadable computer software for genome analysis, developing personal treatment strategies for patients with diagnosed cancer, analyzing, screening, identifying, quantifying, and interpreting data in the field of mass spectrometry
First Use Anywhere:
Sep 17, 2016
First Use in Commerce:
Sep 17, 2016
Class 042
Providing temporary use of on-line nondownloadable software and applications for genome analysis, developing personal treatment strategies for patients with diagnosed cancer; conducting early evaluations in the field of pharmaceuticals; consulting services in the fields of biotechnology and pharmaceutical research; pharmaceutical product development and evaluation services; pharmaceutical research and development; providing medical and scientific research information in the field of pharmaceuticals and clinical trials; research and development of pharmaceuticals for the treatment of cancer; research and development of vaccines and medicines; technical research in the field of pharmaceutical studies; development of platform technology, namely, cancer immunotherapy platforms for manufacturing therapeutics; conducting clinical trials for others in the field of pharmaceuticals for the treatment and prevention of cancer; consulting services for others in the field of design, planning, and implementation of clinical trials; scientific research services, namely, collection of specific molecular and genomic data for analytical and clinical purposes, for the treatment of cancer and other diseases and disorders and for individuals' responses to drug treatments; providing scientific advice in the fields of cancer biology, cancer treatment, pharmaceutical side effects, genomics, cancer medicine and translational medicine; providing scientific analysis in the field of next generation sequencing (NGS), namely, the analysis and interpretation of genomic data obtained from cancer patients; providing an online, non-downloadable computer software platform for purposes of storing and providing information about an individual's cancer profile and genomic changes to enable physicians and healthcare professionals to optimize treatment in clinical practice
First Use Anywhere:
Sep 17, 2016
First Use in Commerce:
Sep 17, 2016
Class 044
healthcare
First Use Anywhere:
Mar 18, 2019
First Use in Commerce:
Mar 18, 2019
Additional Information
Pseudo Mark
GRIT STONE
Classification
International Classes
005
009
042
044